Adham Jammoul1, Luay Shayya1, Karin Mente1, Jianbo Li1, Alexander Rae-Grant1, Yuebing Li1. 1. Neurohospitalist Program (AJ), Aultman Hospital, Canton; and Department of Neurology (LS, KM, AR-G, YL) and Department of Quantitative Health Sciences, Lerner Research Institute (JL), Cleveland Clinic Foundation, OH.
Abstract
BACKGROUND: Antibodies against voltage-gated potassium channel (VGKC)-complex are implicated in the pathogenesis of acquired neuromyotonia, limbic encephalitis, faciobrachial dystonic seizure, and Morvan syndrome. Outside these entities, the clinical value of VGKC-complex antibodies remains unclear. METHODS: We conducted a single-center review of patients positive for VGKC-complex antibodies over an 8-year period. RESULTS: Among 114 patients positive for VGKC-complex antibody, 11 (9.6%) carrying the diagnosis of limbic encephalitis (n = 9) or neuromyotonia (n = 2) constituted the classic group, and the remaining 103 cases of various neurologic and non-neurologic disorders comprised the nonclassic group. The median titer for the classic group was higher than the nonclassic group (p < 0.0001). A total of 90.9% of the patients in the classic and 21.4% in the nonclassic group possessed high (>0.25 nM) VGKC-complex antibody levels (p < 0.0001). A total of 75.0% of the patients in the high-level group had definite or probable autoimmune basis, while nonautoimmune disorders were seen in 75.6% of patients from the low-level group (p < 0.0001). A total of 26.3% of patients were found with active or remote solid organ or hematologic malignancy, but no antibody titer difference was observed among subgroups of absent, active, or remote malignancy. Compared to age-matched US national census, rates of active cancer in our cohort were higher in patients older than 45 years. CONCLUSIONS: High VGKC-complex antibody titers are more likely found in patients with classically associated syndromes and other autoimmune conditions. Low-level VGKC-complex antibodies can be detected in nonspecific and mostly nonautoimmune disorders. The presence of VGKC-complex antibody, rather than its level, may serve as a marker of malignancy.
BACKGROUND: Antibodies against voltage-gated potassium channel (VGKC)-complex are implicated in the pathogenesis of acquired neuromyotonia, limbic encephalitis, faciobrachial dystonic seizure, and Morvan syndrome. Outside these entities, the clinical value of VGKC-complex antibodies remains unclear. METHODS: We conducted a single-center review of patients positive for VGKC-complex antibodies over an 8-year period. RESULTS: Among 114 patients positive for VGKC-complex antibody, 11 (9.6%) carrying the diagnosis of limbic encephalitis (n = 9) or neuromyotonia (n = 2) constituted the classic group, and the remaining 103 cases of various neurologic and non-neurologic disorders comprised the nonclassic group. The median titer for the classic group was higher than the nonclassic group (p < 0.0001). A total of 90.9% of the patients in the classic and 21.4% in the nonclassic group possessed high (>0.25 nM) VGKC-complex antibody levels (p < 0.0001). A total of 75.0% of the patients in the high-level group had definite or probable autoimmune basis, while nonautoimmune disorders were seen in 75.6% of patients from the low-level group (p < 0.0001). A total of 26.3% of patients were found with active or remote solid organ or hematologic malignancy, but no antibody titer difference was observed among subgroups of absent, active, or remote malignancy. Compared to age-matched US national census, rates of active cancer in our cohort were higher in patients older than 45 years. CONCLUSIONS: High VGKC-complex antibody titers are more likely found in patients with classically associated syndromes and other autoimmune conditions. Low-level VGKC-complex antibodies can be detected in nonspecific and mostly nonautoimmune disorders. The presence of VGKC-complex antibody, rather than its level, may serve as a marker of malignancy.
Authors: Liane Dahm; Christoph Ott; Johann Steiner; Beata Stepniak; Bianca Teegen; Sandra Saschenbrecker; Christian Hammer; Kathrin Borowski; Martin Begemann; Sandra Lemke; Kristin Rentzsch; Christian Probst; Henrik Martens; Jürgen Wienands; Gianfranco Spalletta; Karin Weissenborn; Winfried Stöcker; Hannelore Ehrenreich Journal: Ann Neurol Date: 2014-06-23 Impact factor: 10.422
Authors: Angela Vincent; Camilla Buckley; Jonathan M Schott; Ian Baker; Bonnie-Kate Dewar; Niels Detert; Linda Clover; Abigail Parkinson; Christian G Bien; Salah Omer; Bethan Lang; Martin N Rossor; Jackie Palace Journal: Brain Date: 2004-02-11 Impact factor: 13.501
Authors: Hesham Abboud; Ian Rossman; Maureen A Mealy; Eddie Hill; Nicolas Thompson; Aditya Banerjee; John Probasco; Michael Levy Journal: J Neurol Date: 2017-10-03 Impact factor: 4.849
Authors: Hesham Abboud; John Probasco; Sarosh R Irani; Beau Ances; David R Benavides; Michael Bradshaw; Paulo Pereira Christo; Russell C Dale; Mireya Fernandez-Fournier; Eoin P Flanagan; Avi Gadoth; Pravin George; Elena Grebenciucova; Adham Jammoul; Soon-Tae Lee; Yuebing Li; Marcelo Matiello; Anne Marie Morse; Alexander Rae-Grant; Galeno Rojas; Ian Rossman; Sarah Schmitt; Arun Venkatesan; Steven Vernino; Sean J Pittock; Maarten Titulaer Journal: J Neurol Neurosurg Psychiatry Date: 2021-03-01 Impact factor: 13.654